| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
305.10(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-01-30 |
4 |
AS |
$19.50 |
$64,351 |
D/D |
(3,300) |
2,466 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-01-30 |
4 |
OE |
$0.38 |
$1,254 |
D/D |
3,300 |
5,766 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-01-29 |
4 |
AS |
$17.77 |
$1,082,634 |
D/D |
(60,000) |
2,466 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-01-29 |
4 |
OE |
$0.38 |
$22,800 |
D/D |
60,000 |
62,466 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2015-01-28 |
4 |
AS |
$17.98 |
$1,444,304 |
D/D |
(80,000) |
0 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-01-28 |
4 |
AS |
$17.97 |
$1,536,515 |
D/D |
(85,000) |
2,466 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2015-01-28 |
4 |
OE |
$0.38 |
$32,300 |
D/D |
85,000 |
87,466 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2014-12-12 |
4 |
OE |
$0.38 |
$57,000 |
D/D |
150,000 |
150,000 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2014-11-28 |
4 |
AS |
$18.80 |
$48,245 |
D/D |
(2,500) |
80,000 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2014-11-28 |
4 |
OE |
$1.74 |
$4,350 |
D/D |
2,500 |
82,500 |
|
- |
|
| Astrazeneca Ab |
10% Owner |
– – • |
2014-11-12 |
4 |
S |
$17.00 |
$34,000,000 |
I/I |
(2,000,000) |
4,250,000 |
|
- |
|
| Parshall B Lynne |
Director |
– • – |
2014-11-03 |
4 |
S |
$15.94 |
$20,390,613 |
D/D |
(1,279,411) |
5,516,305 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2014-10-29 |
4 |
AS |
$18.66 |
$67,824 |
D/D |
(3,505) |
2,466 |
|
- |
|
| Xanthopoulos Kleanthis G |
President and CEO |
• • – |
2014-10-29 |
4 |
OE |
$0.38 |
$1,332 |
D/D |
3,505 |
5,971 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2014-10-29 |
4 |
AS |
$18.68 |
$48,234 |
D/D |
(2,500) |
80,000 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2014-10-29 |
4 |
OE |
$1.74 |
$4,350 |
D/D |
2,500 |
82,500 |
|
- |
|
| Isis Pharmaceuticals Inc |
Director |
– • • |
2014-10-24 |
4/A |
AS |
$14.63 |
$28,109 |
D/D |
(1,850) |
6,795,716 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-10-24 |
4 |
AS |
$15.19 |
$28,109 |
D/D |
(1,850) |
6,795,716 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-10-24 |
4 |
AS |
$15.19 |
$28,109 |
D/D |
(1,850) |
5,896,716 |
|
- |
|
| Isis Pharmaceuticals Inc |
Director |
– • • |
2014-10-23 |
4/A |
AS |
$13.94 |
$24,202 |
D/D |
(1,700) |
6,797,566 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-10-23 |
4 |
AS |
$14.24 |
$24,202 |
D/D |
(1,700) |
6,797,566 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-10-23 |
4 |
AS |
$14.24 |
$24,202 |
D/D |
(1,700) |
5,898,566 |
|
- |
|
| Isis Pharmaceuticals Inc |
Director |
– • • |
2014-10-22 |
4/A |
AS |
$12.18 |
$1,533,135 |
D/D |
(109,534) |
6,799,266 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2014-10-22 |
4 |
AS |
$14.44 |
$47,644 |
D/D |
(3,300) |
80,000 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2014-10-22 |
4 |
OE |
$1.74 |
$5,742 |
D/D |
3,300 |
83,300 |
|
- |
|
306 Records found
|
|
Page 7 of 13 |
|
|
0.12 (5.43%) 
